Back

Age-related differences in rejection rates, infections and tacrolimus exposure in pediatric kidney transplant recipients - a benchmark study of the CERTAIN registry

Baghai Arassi, M.; Feisst, M.; Krupka, K.; Awan, A.; Benetti, E.; Duzova, A.; Guzzo, I.; Kim, J. J.; Koenig, S.; Litwin, M.; Oh, J.; Pape, L.; Buecher, A.; Peruzzi, L.; Shenoy, M.; Testa, S.; Weber, L. T.; Zieg, J.; Hoecker, B.; Fichtner, A.; Toenshoff, B.

2024-05-27 transplantation
10.1101/2024.05.27.24307975
Show abstract

BackgroundData on age-related differences in rejection rates, infectious episodes and tacrolimus exposure in pediatric kidney transplant recipients (pKTR) on a uniform tacrolimus-based immunosuppressive regimen are scarce. MethodsWe therefore performed a large-scale analysis of 802 pKTR from the CERTAIN registry from 40 centers in 14 countries. Inclusion criteria were a tacrolimus-based immunosuppressive regimen and at least two years of follow-up. The patient population was divided into three age groups (infants <6 years, school-aged children 6-12 years, and adolescents >12 years) to assess age-related differences in outcome. ResultsMedian follow-up was 48 months (IQR, 36-72). Within the first 2 years post-transplant, infants had a significantly higher incidence of infections (80.6% vs. 55.0% in adolescents, P<0.001) and a significantly higher number of cumulative hospital days (median 13 days vs. 7 days in adolescents, P < 0.001). Adolescents had a significantly higher rate of biopsy-proven acute rejection episodes in the first year post-transplant (21.7%) than infants (12.6%, P=0.007). Infants had significantly lower tacrolimus trough levels, lower concentration-to-dose ratios as an approximation for higher tacrolimus clearance, and higher intra-patient variability (all P < 0.01) than adolescents. ConclusionsThis largest study to date in European pKTR on a tacrolimus-based immunosuppressive regimen shows important age-related differences in rejection rates, infection episodes, tacrolimus exposure and clearance. These data suggest that immunosuppressive therapy in pKTR should be tailored according to the age-specific risk profiles of this heterogeneous patient population.

Matching journals

The top 3 journals account for 50% of the predicted probability mass.